The societal cost of modifiable risk factors in Singapore.
Global Burden of Disease
Modifiable risk factors
Population attributable fraction
Societal cost
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
received:
25
04
2023
accepted:
27
06
2023
medline:
6
7
2023
pubmed:
5
7
2023
entrez:
4
7
2023
Statut:
epublish
Résumé
Singapore is one of the most rapidly ageing populations in the world. Nearly half of all disease burdens in Singapore are attributable to modifiable risk factors. This indicates that many illnesses are preventable by modifying behaviours such as increasing physical activity levels or maintaining a healthy diet. Prior cost-of-illness studies have estimated the cost of selected modifiable risk factors. However, no local study has compared costs between groups of modifiable risks. This study aims to estimate the societal cost attributable to a comprehensive list of modifiable risks in Singapore. Our study builds on the comparative risk assessment framework from the Global Burden of Disease (GBD) 2019 study. A top-down prevalence-based cost-of-illness approach was undertaken to estimate the societal cost of modifiable risks in 2019. These include healthcare costs from inpatient hospitalisation and productivity losses from absenteeism and premature mortality. Metabolic risks had the highest total cost of US$1.62 billion (95% uncertainty interval [UI] US$1.51-1.84 billion), followed by lifestyle risks of US$1.40 billion (95% UI US$1.36-1.66 billion) and substance risks of US$1.15 billion (95% UI US$1.10-1.24 billion). Across the risk factors, the costs were driven by productivity losses, heavily skewed towards the older working-age group and among males. Most of the costs were driven by cardiovascular diseases. This study provides evidence of the high societal cost of modifiable risks and highlights the importance of developing holistic public health promotion programmes. As modifiable risks often do not occur in isolation, implementing effective population-based programmes targeting multiple modifiable risks has a strong potential to manage the cost of the rising disease burden in Singapore.
Sections du résumé
BACKGROUND
Singapore is one of the most rapidly ageing populations in the world. Nearly half of all disease burdens in Singapore are attributable to modifiable risk factors. This indicates that many illnesses are preventable by modifying behaviours such as increasing physical activity levels or maintaining a healthy diet. Prior cost-of-illness studies have estimated the cost of selected modifiable risk factors. However, no local study has compared costs between groups of modifiable risks. This study aims to estimate the societal cost attributable to a comprehensive list of modifiable risks in Singapore.
METHODS
Our study builds on the comparative risk assessment framework from the Global Burden of Disease (GBD) 2019 study. A top-down prevalence-based cost-of-illness approach was undertaken to estimate the societal cost of modifiable risks in 2019. These include healthcare costs from inpatient hospitalisation and productivity losses from absenteeism and premature mortality.
RESULTS
Metabolic risks had the highest total cost of US$1.62 billion (95% uncertainty interval [UI] US$1.51-1.84 billion), followed by lifestyle risks of US$1.40 billion (95% UI US$1.36-1.66 billion) and substance risks of US$1.15 billion (95% UI US$1.10-1.24 billion). Across the risk factors, the costs were driven by productivity losses, heavily skewed towards the older working-age group and among males. Most of the costs were driven by cardiovascular diseases.
CONCLUSION
This study provides evidence of the high societal cost of modifiable risks and highlights the importance of developing holistic public health promotion programmes. As modifiable risks often do not occur in isolation, implementing effective population-based programmes targeting multiple modifiable risks has a strong potential to manage the cost of the rising disease burden in Singapore.
Identifiants
pubmed: 37403019
doi: 10.1186/s12889-023-16198-2
pii: 10.1186/s12889-023-16198-2
pmc: PMC10318651
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Eur Respir J. 2016 Sep;48(3):889-902
pubmed: 27174888
Indian J Endocrinol Metab. 2012 Mar;16(2):240-5
pubmed: 22470861
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Br J Nutr. 2022 May 26;:1-9
pubmed: 35614498
Ann Epidemiol. 2015 Mar;25(3):147-54
pubmed: 25721747
BMC Public Health. 2016 Jul 29;16:657
pubmed: 27473458
PLoS One. 2015 Mar 27;10(3):e0122795
pubmed: 25816299
Ugeskr Laeger. 2008 Aug 11;170(33):2434-7
pubmed: 18761824
Lancet. 2016 Sep 24;388(10051):1311-24
pubmed: 27475266
BMJ Glob Health. 2019 Jan 10;4(1):e001144
pubmed: 30713746
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Chronic Dis Inj Can. 2013 Sep;33(4):236-46
pubmed: 23987220
PLoS One. 2021 Apr 26;16(4):e0250282
pubmed: 33901204
J Pediatr. 2020 Apr;219:31-37.e6
pubmed: 32061408
PLoS One. 2018 Apr 27;13(4):e0196333
pubmed: 29702680
Prev Med. 2007 Feb;44(2):124-8
pubmed: 17157369
Lancet Public Health. 2020 Oct;5(10):e525-e535
pubmed: 33007211
Eur J Health Econ. 2022 Feb;23(1):33-45
pubmed: 34236544
BMC Public Health. 2010 Dec 24;10:789
pubmed: 21184680
J Am Heart Assoc. 2020 Apr 7;9(7):e014381
pubmed: 32264731
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Int J Environ Res Public Health. 2020 Mar 14;17(6):
pubmed: 32183392
Int J Stroke. 2015 Oct;10 Suppl A100:75-82
pubmed: 26179153
J Diabetes Res. 2020 Jul 01;2020:6478393
pubmed: 32714993
Clin Mol Hepatol. 2014 Dec;20(4):327-37
pubmed: 25548737
Psychol Sci. 2008 Oct;19(10):1037-44
pubmed: 19000215
BMJ Open. 2017 Apr 7;7(4):e014377
pubmed: 28389491
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Prev Med. 2015 Dec;81:16-41
pubmed: 26190368
Am J Prev Med. 2004 Apr;26(3):243-9
pubmed: 15026106
Tob Control. 2018 Jan;27(1):58-64
pubmed: 28138063
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Aust N Z J Med. 1999 Apr;29(2):228-33
pubmed: 10342022